Rapport Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 |
|---|---|---|---|
| Operating income | -$125.1M | -$83.1M | -$36.2M |
| Operating expenses | $125.1M | $83.1M | $36.2M |
| Cash from operations | -$87.5M | -$64.8M | -$27.2M |
| Capital expenditure | $616,000 | $2.4M | $1.6M |
| Free cash flow | -$88.1M | -$67.2M | -$28.8M |
| Share repurchases | $1,000 | — | $4,000 |
| Impairments | $0 | $0 | $0 |
| Total assets | $512.4M | $314.9M | $155.4M |
| Total liabilities | $27.8M | $9.5M | $14.5M |
Shares outstanding 47.8M · Free float 64.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.